Interpreting Divergent Short-Chain Fatty Acid Effects in Alzheimer's Disease: A Seven-Axis Framework

Area of Science:

• Neuroscience
• Pharmacology
• Microbiome Research

Background:

• Studies on short-chain fatty acids (SCFAs) in Alzheimer's disease (AD) yield inconsistent results, ranging from protective to adverse effects.
• This heterogeneity stems from variations in SCFA types, doses, administration routes, and the specific biological contexts studied.

Purpose of the Study:

• To propose a novel interpretive framework for organizing and comparing diverse SCFA research in Alzheimer's disease.
• To address the inconsistencies in SCFA findings by establishing a causal sequence from exposure to endpoint.

Main Methods:

• Development of a seven-axis framework: SCFA species, dose, route, compartment, exposure context, disease stage, and responding cell type.
• Distinguishing between administered dose and achieved exposure, and between direct central nervous system entry and peripheral signaling.
• Emphasizing symmetric interpretation of null findings based on exposure verification, target engagement, and study power.

Main Results:

• The framework provides a structured approach to analyze SCFA's complex role in AD, separating key variables that influence outcomes.
• It highlights the need to consider specific exposure details, disease progression, and cellular responses for accurate interpretation of SCFA effects.
• The framework integrates existing knowledge from microbiome, pharmacology, and neuroimmunology.

Conclusions:

• The proposed framework facilitates a more nuanced understanding of SCFA actions in AD, moving beyond generalized class labels.
• It advocates for mechanism-linked, biomarker-informed research over non-specific SCFA supplementation in unselected Alzheimer's patients.
• Further validation through meta-regression and replication studies is suggested to test the framework's explanatory power.